ARS Pharmaceuticals, Inc. (SPRY) Upgraded to Buy: Here’s Why
ZacksARS Pharmaceuticals, Inc. (SPRY) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company’s earnings prospects. This might drive the stock higher in the near term.